CERS
Cerus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CERS
Cerus Corporation
A company that develops blood safety systems to inactivate blood-borne pathgens in components intended for transfusion
Healthcare Equipment and Supplies
--
01/30/1997
NASDAQ Stock Exchange
281
12-31
Common stock
1220 Concord Avenue, Suite 600, Concord, California 94520
--
Cerus Corporation, founded in California in 1991 and re-incorporated in Delaware in 1996. The Company is a biomedical products company focused on developing and commercializing the INTERCEPT blood system to enhance blood safety. The Company's INTERCEPT blood system is designed to work with blood components and certain of their derivatives: platelets, plasma, red blood cells and the production of INTERCEPT fibrinogen complex, or IFC, as well as pathogen-reducing plasma, cryoprecipitate reduction.
Earnings Call
Q1/2025
Estimate EPS-0.05
Actual EPS-0.04
Estimate Revenue47.44M
Actual Revenue43.24M
Cerus's Q1 2025 Earnings Call: Unpacking Contradictions in Market Share, Cost Guidance, and Growth Prospects
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.02
Actual EPS-0.03
Estimate Revenue51.80M
Actual Revenue60.10M
Cerus Corporation's Q2 2025: Navigating Contradictions in Supply Dynamics, Revenue Growth, and Demand Expectations
Aug 05,2025 09:12
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CERS has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected -0.03, beating expectations. The chart below visualizes how CERS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CERS has released its 2025 Q3 earnings report, with revenue of 60.24M, reflecting a YoY change of 18.91%, and net profit of -20.00K, showing a YoY change of 99.32%. The Sankey diagram below clearly presents CERS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
